Company profile: Normunity
1.1 - Company Overview
Company description
- Provider of precision immuno-oncology medicines focused on immune normalizers—novel cancer immunotherapies that restore normal immune responses. Includes the Chen Lab Discovery Platform to identify and validate novel targets and Normunity Drug Development to create monoclonal antibodies based on these discoveries.
Products and services
- Immune Normalizers: Precision immuno-oncology medicines constituting a new class that targets novel mechanisms to restore the normal immune system’s ability to fight cancer, enabling normal immunity against cancer
- Normunity Drug Development: Antibody-based immunotherapy development that architects new cancer treatments, including monoclonal antibodies, built on Chen Lab discoveries to translate novel target insights into new therapies
- Chen Lab Discovery Platform: Research platform that identifies and validates novel immunotherapy targets by analyzing interactions between cancer and the immune system, supporting development of cancer immunotherapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Normunity
Modifi Bio
HQ: United States
Website
- Description: Provider of direct DNA modification cancer therapeutics, including orally delivered molecules that selectively kill cancer cells by modifying tumor DNA while preserving healthy cells. Products target cancers with DNA repair defects and MGMT deficiency, with applications in glioblastomas, gliomas, and potentially other MGMT-deficient tumor types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Modifi Bio company profile →
IconOVir Bio
HQ: United States
Website
- Description: Provider of preclinical oncolytic virus therapies for cancer, developing ICVB-1042, an oncolytic adenovirus for advanced solid tumors featuring tumor-selective replication, broad tropism, and enhanced tumor cell killing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IconOVir Bio company profile →
Blue Earth Diagnostics
HQ: United Kingdom
Website
- Description: Provider of molecular PET imaging agents and technologies for cancer diagnosis, developing and commercialising radiopharmaceuticals addressing high unmet medical needs. Offerings include Axumin (fluciclovine F 18) for detecting recurrent prostate cancer, POSLUMA (flotufolastat F 18) Injection for detecting prostate cancer, FAP-targeted PET technology for multiple solid tumors, and clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blue Earth Diagnostics company profile →
Argos Therapeutics
HQ: United States
Website
- Description: Provider of immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. Conducts clinical trial programs in cancer and HIV. Product candidates include AGS-0031 for metastatic renal cell carcinoma, AGS-0041 for HIV, and CD83.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Argos Therapeutics company profile →
U-Systems
HQ: United States
Website
- Description: Provider of automated breast ultrasound systems and software that deliver automated breast scans to assist radiologists in detecting breast cancer, particularly in women with dense breast tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full U-Systems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Normunity
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Normunity
2.2 - Growth funds investing in similar companies to Normunity
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Normunity
4.2 - Public trading comparable groups for Normunity
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →